Wachtell and Cravath lead for Pfizer/Mylan merger
Pfizer and Mylan have tapped Wachtell Lipton Rosen & Katz and Cravath Swaine & Moore, respectively, to oversee the proposed combination of Pfizer’s Upjohn and generic drugmaker Mylan.
To read more
Subscribe to Global Competition Review
Subscribe and start reading now